Skip to main content

Advertisement

SpringerLink
Log in

Prevention of left ventricular remodeling after myocardial infarction

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Postinfarction left ventricular remodeling begins early after acute myocardial infarction and may continue for months to years afterward. Early re-establishment of flow in the occluded artery is associated with smaller left ventricular cavity volumes and reduced remodeling. Acute percutaneous coronary intervention (PCI) or thrombolytic therapy (for patients more than 1 hour away from a catheterization facility) as early as possible after symptoms is critical. Late reperfusion (PCI more than 12 hours after infarction) may prove useful, and this will be determined by the results of ongoing clinical trials. Recurrent MI is reduced by antiplatelet agents (aspirin in most patients) and by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Intravenous nitroglycerin may limit early (initial 24 hours) dilatation following infarction, but long-term use in asymptomatic patients is not efficacious. Betaadrenergic receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors have independent efficacy in attenuating the early and late phases of remodeling. The combined use of a beta-blocker and an ACE inhibitor has greater efficacy than either agent alone, provided they are tolerated hemodynamically. Although angiotensin II receptor antagonists have similar efficacy to ACE inhibitors and have fewer side effects, the angiotensin II receptor blockers should be reserved for patients intolerant to ACE inhibitors. In patients requiring diuretic therapy, spironolactone is preferred because of its salutary properties regarding extracellular matrix remodeling, specifically in reducing fibrosis. Surgical revascularization with or without associated mitral valve repair is useful in selected patients with severe ischemic mitral regurgitation or hibernating myocardium. New therapies directed at modulating the remodeling process may focus on manipulating the components of the extracellular matrix to reduce the deleterious impact of this process.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Yousef ZR, Redwood SR, Marber MS: Postinfarction left ventricular remodeling: where are the theories and trials leading us? Heart 2000, 83:76–80.

    Article  PubMed  CAS  Google Scholar 

  2. Jugdutt B, Warnica J: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage, and infarct location. Circulation 1988, 78:906–919.

    PubMed  CAS  Google Scholar 

  3. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute MI. Lancet 1995, 345:669–685.

    Article  Google Scholar 

  4. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto: GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on six-week mortality and ventricular function after acute MI. Lancet 1994, 343:1115–1122.

    Google Scholar 

  5. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429–1435.

    Article  Google Scholar 

  6. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293–302.

    Article  Google Scholar 

  7. Pfeffer M, Braunwald E, Moye L, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after MI: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992, 327:669–677. The earliest major clinical trial to demonstrate the efficacy of pharmacological therapy in limiting postinfarction remodeling.

    Article  PubMed  CAS  Google Scholar 

  8. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.

    Article  Google Scholar 

  9. St. John Sutton M, Pfeffer MA, Moye L, et al.: Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997, 96:3294–3299.

    PubMed  CAS  Google Scholar 

  10. St. John Sutton M, Pfeffer MA, Plappert T, et al.: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89:68–75.

    PubMed  CAS  Google Scholar 

  11. ACE Inhibitor MI Collaborative Group: Indications for ACE inhibitors in the early treatment of acute MI: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998, 97:2202–2212.

    Google Scholar 

  12. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) study investigators. N Engl J Med 1995, 332:80–85.

    Article  PubMed  CAS  Google Scholar 

  13. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995, 345:686–687.

    Article  Google Scholar 

  14. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. An important trial of nearly 10,000 patients across a broad risk group, 50% of whom had prior infarction, demonstrating a significant reduction in cardiovascular events and mortality in patients with no overt heart failure symptoms or left ventricular dysfunction.

    Article  PubMed  CAS  Google Scholar 

  15. Pitt B, Segal R, Martinez F, et al.: Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly, ELITE). Lancet 1997, 349:747–752.

    Article  PubMed  CAS  Google Scholar 

  16. Pitt B, Poole-Wilson P, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  17. Struthers A: Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996, 2:47–54.

    Article  PubMed  CAS  Google Scholar 

  18. .PittB, Zannad F, Remme W, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717. Recent trial demonstrating the survival benefits afforded by spironolactone when added to standard heart failure therapy. May have major impact of future therapy of heart failure.

    Article  PubMed  CAS  Google Scholar 

  19. Yusuf S, Peto R, Lewis J, et al.: Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335–371.

    Article  PubMed  CAS  Google Scholar 

  20. CIBIS Investigators and Committee: A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study. Circulation 1994, 90:1765–1773.

    Google Scholar 

  21. CIBIS-II Investigators Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 1999, 353:9–13.

    Article  Google Scholar 

  22. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999, 353:2001–2007.

    Article  Google Scholar 

  23. Packer M, Coats A, Fowler M, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658.

    Article  PubMed  CAS  Google Scholar 

  24. Gottlieb S, McCarter R, Vogel R: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489–497.

    Article  PubMed  CAS  Google Scholar 

  25. Aronow W, Ahn C, Kronzon I: Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001, 88:1298–1300.

    Article  PubMed  CAS  Google Scholar 

  26. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569–582.

    Article  PubMed  CAS  Google Scholar 

  27. Doughty R, Whalley G, Gamble G, et al.: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease: Australia-New Zealand Heart Failure Research Collaborative Group. Am Coll Cardiol 1997, 29:1060–1066.

    Article  CAS  Google Scholar 

  28. Senior R, Basu S, Kinsey C, et al.: Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 1999, 137:646–652.

    Article  PubMed  CAS  Google Scholar 

  29. Bolognese L, Cerisano G: Early predictors of left ventricular remodeling after acute myocardial infarction. Am Heart J 1999, 138:S79-S83.

    Article  PubMed  CAS  Google Scholar 

  30. Lamas G, Flaker G, Mitchell G, et al.: Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation 1995, 92:1101–1109. One of the earliest clinical studies to demonstrate the survival benefits of successful reperfusion therapy and of a patent infarct-related artery.

    PubMed  CAS  Google Scholar 

  31. Marino P, Zanolla L, Zardini P: Effect of streptokinase on left ventricular remodeling and function after myocardial infarction: the GISSI trial. J Am Coll Cardiol 1989, 14:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  32. Touchstone D, Beller G, Nygaard T, et al.: Effects of successful intravenous reperfusion therapy on regional myocardial function and geometry in humans: a topographic assessment using twodimensional echocardiography. J Am Coll Cardiol 1989, 13:1506–1513.

    Article  PubMed  CAS  Google Scholar 

  33. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993, 342:759–766.

  34. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group: Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993, 342:767–772.

    Article  Google Scholar 

  35. Hochman JS, Choo H: Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987, 75:299–306.

    PubMed  CAS  Google Scholar 

  36. Sheiban I, Fragasso G, Rosano G, et al.: Time course and determinants of left ventricular function recovery after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2001, 38:464–471.

    Article  PubMed  CAS  Google Scholar 

  37. Morishima I, Sone T, Okumura K, et al.: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000, 36:1202–1209.

    Article  PubMed  CAS  Google Scholar 

  38. Dzavik V, Carere R, Mancini G, et al.: Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). Am Heart J 2001, 142:301–308.

    Article  PubMed  CAS  Google Scholar 

  39. Senior R, Kaul S, Lahiri A: Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 1999, 33:1848–1854.

    Article  PubMed  CAS  Google Scholar 

  40. Liel-Cohen N, Guerrero J, Otsuji Y, et al.: Design of a new surgical approach for ventricular remodeling to relieve ischemic mitral regurgitation: insights from 3-dimensional echocardiography. Circulation 2001, 101:2756–2763.

    Google Scholar 

  41. Spinale F, Coker M, Kromback S, et al.: Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 1999, 85:364–376.

    PubMed  CAS  Google Scholar 

  42. Ducharme A, Frantz S, Aikawa M, et al.: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000, 106:55–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 9022 East Gates Pavilion, 19104, Philadelphia, PA, USA

    Martin St. John Sutton MBBS, FRCP & Victor A. Ferrari MD

Authors
  1. Martin St. John Sutton MBBS, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor A. Ferrari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sutton, M.S.J., Ferrari, V.A. Prevention of left ventricular remodeling after myocardial infarction. Curr Treat Options Cardio Med 4, 97–108 (2002). https://doi.org/10.1007/s11936-002-0030-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-002-0030-4

Keywords

Search

Navigation